Pharmaceutical News

RSS

Cancer drug can neutralize toxic RNA that causes myotonic dystrophy

A group of researchers has shown for the first time in cells and in a mouse model that a drug used to treat cancer can neutralize the toxic RNA that causes the prolonged muscle contractions and other symptoms of myotonic dystrophy type 1, the most common form of adult-onset muscular dystrophy.

11 Dec 2015

Marqibo now available to leukemia patients through myTomorrows' Internet-based platform

myTomorrows (Amsterdam, the Netherlands), announced today that it has started a collaboration with Spectrum Pharmaceuticals, Inc. (Henderson, USA) to provide access to its liposome-encapsulated vincristine for treatment of Philadelphia chromosome negative acute lymphoblastic leukemia.

10 Dec 2015

Ajinomoto Althea expands biological drug product manufacturing operations

Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs).

10 Dec 2015

New heart failure drug may increase patients' risk of Alzheimer's disease, macular degeneration

Patients with mild heart failure stand to benefit from a new drug that can halt the progression of their disease and reduce their risk of cardiovascular-related death. But the drug -- a tablet that combines the agents valsartan and sacubitril, sold under the trade name Entresto by drugmaker Novartis -- may be too good to be true, according to Arthur M. Feldman, MD, PhD, Executive Dean of the Lewis Katz School of Medicine at Temple University, Chief Academic Officer of the Temple University Health System, and Laura H. Carnell Professor of Medicine at LKSOM.

10 Dec 2015

New class of diabetes drugs differs in efficacy and safety profiles, shows new research

Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) differ in their efficacy and safety profiles, according to new research by the University of Leicester.

10 Dec 2015

Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast cancer patients

Giving a monoclonal antibody (denosumab) as adjuvant therapy with aromatase inhibitors in postmenopausal, hormone-receptor-positive breast cancer patients reduces the relapse rate by 18%. This is the central finding of the ABCSG 18 breast cancer study regarding disease-free survival.

10 Dec 2015

More than half of U.S. hospitals don't require flu shots for staff, new study finds

Within weeks, flu will start spreading across North America, sickening millions of people. It will hit people with health problems and weak immune systems hardest, and may kill tens of thousands of them.

10 Dec 2015

Research examines ketone esters to combat hyperbaric oxygen toxicity in Navy divers

For the first time, ketone esters-oral supplements useful in epilepsy treatment-are being studied to fight seizures caused by hyperbaric oxygen toxicity, a life-threatening byproduct of breathing too much oxygen that impacts deep-water divers.

9 Dec 2015

Aspirin does not improve survival among breast cancer patients with aggressive disease

Whether aspirin may help prevent or reduce the risk of breast cancer remains a hotly debated research question. While past studies have indicated a potential benefit, most recently in hormone receptor-positive breast cancers, one new study from Penn Medicine suggests otherwise.

9 Dec 2015

Palbociclib and paclitaxel combination shrinks tumors in patient with ER positive breast cancer

Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patient with estrogen-receptor (ER) positive breast cancer, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

9 Dec 2015

New drug therapies that target glutamate pathway may be effective for subgroups of patient with schizophrenia

Mounting evidence indicates that disturbances in the brain's glutamate pathway contribute to symptoms of schizophrenia. Thus, the glutamate pathway has become the target of a number of new drug therapies. Findings published in the journal Biological Psychiatry suggest that at least one of these drugs may be an effective treatment for individuals in the early course of the illness.

9 Dec 2015

FDA approves recombinant von Willebrand factor for treating bleeding episodes in adults with VWD

The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD.

8 Dec 2015

Oxitec prepares to increase supplies of OX513A to address recent outbreak of Zika virus in Brazil

Intrexon Corporation, a leader in synthetic biology, today announced that Oxitec, a UK-based subsidiary of the Company, is prepared to increase supplies of its proprietary mosquito control solution, OX513A, through its Brazil facilities to assist Brazil in addressing the recent devastating outbreak of the Zika virus and other diseases transmitted by the Aedes aegypti mosquito.

8 Dec 2015

Kanuma approved as first treatment for patients with LAL deficiency

Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.

8 Dec 2015

SRI Biosciences, SCI collaborate to develop novel compounds to treat multiple forms of cancer

A new collaborative program between scientists at SRI Biosciences, a division of SRI International, and physician-researchers from Stanford Cancer Institute will pursue development of novel compounds to treat multiple forms of cancer and other conditions.

8 Dec 2015

Existing compound offers hope for slowing Huntington's disease progression

Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.

8 Dec 2015

Researchers discover 'triple attack' technique to target liver cancer tumors

In an interdisciplinary collaboration between prominent academic and industry investigators, researchers have discovered a novel method for repositioning an FDA-approved anti-cancer compound so it can specifically target liver cancer tumors. A 'triple attack' technique combining chemotherapy, thermal ablation, and hyperthermia provided a highly targeted, yet minimally invasive approach.

8 Dec 2015

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) - the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini - as an orphan drug for the treatment of neurotrophic keratitis.

8 Dec 2015

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla's CAB platform and utilizing Pfizer's proprietary antibody drug conjugate (ADC) payloads.

8 Dec 2015

FDA clears use of XSTAT 30 wound dressing to control severe bleeding in civilian population

Today, the U.S. Food and Drug Administration cleared the use of the XSTAT 30 wound dressing, an expandable, multi-sponge dressing used to control severe, life-threatening bleeding from wounds in areas that a tourniquet cannot be placed (such as the groin or armpit) in battlefield and civilian trauma settings.

8 Dec 2015

Pharmaceutical News

Cancer drug can neutralize toxic RNA that causes myotonic dystrophy

Marqibo now available to leukemia patients through myTomorrows' Internet-based platform

Ajinomoto Althea expands biological drug product manufacturing operations

New heart failure drug may increase patients' risk of Alzheimer's disease, macular degeneration

New class of diabetes drugs differs in efficacy and safety profiles, shows new research

Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast cancer patients

More than half of U.S. hospitals don't require flu shots for staff, new study finds

Research examines ketone esters to combat hyperbaric oxygen toxicity in Navy divers

Aspirin does not improve survival among breast cancer patients with aggressive disease

Palbociclib and paclitaxel combination shrinks tumors in patient with ER positive breast cancer

New drug therapies that target glutamate pathway may be effective for subgroups of patient with schizophrenia

FDA approves recombinant von Willebrand factor for treating bleeding episodes in adults with VWD

Oxitec prepares to increase supplies of OX513A to address recent outbreak of Zika virus in Brazil

Kanuma approved as first treatment for patients with LAL deficiency

SRI Biosciences, SCI collaborate to develop novel compounds to treat multiple forms of cancer

Existing compound offers hope for slowing Huntington's disease progression

Researchers discover 'triple attack' technique to target liver cancer tumors

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

FDA clears use of XSTAT 30 wound dressing to control severe bleeding in civilian population

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News